| |
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
Today’s Big NewsMar 28, 2025 |
|
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot!
|
|
| By Angus Liu After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. |
|
|
|
By Nick Paul Taylor Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice. |
By Angus Liu As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is courting foreign investment as well, including from drugmakers. |
By Conor Hale Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation. |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now.
|
|
By Andrea Park Kate Cronin, who took the marketing reins at Moderna in 2021 as it was skyrocketing to global renown for its COVID-19 vaccine, is stepping down from her post. |
By Darren Incorvaia Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests certain approved drugs could possibly be repurposed for a severe fatigue condition that currently has no approved treatment, while also highlighting prospective targets for new therapeutics. A week later, the NIH terminated grant funding to Columbia's center studying the condition. |
By Kevin Dunleavy Over the last three years, the FDA has approved six new drugs for hemophilia. And now the U.S. regulator has signed off on another, Sanofi’s Qfitlia, which sets itself apart as the only treatment for all types of hemophilia. |
By Kevin Dunleavy Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of $23.7 million last year, a 5% boost on his $22.6 million pay from 2023. |
By Darren Incorvaia,Zoey Becker CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the company’s executive team. Bruno had been with CRISPR for six years, serving in several management roles with increasing responsibility before landing the chief operating officer position last May. |
By Nick Paul Taylor BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and Roche. |
By Conor Hale Visby's kit includes vaginal self-collection swabs and a palm-sized, PCR-based testing device for chlamydia, gonorrhea and trichomoniasis, which delivers a result within 30 minutes. |
By Zoey Becker After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators. |
By James Waldron BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic antibodies while eking out its cash to cover a slew of clinical readouts over the next couple of years. |
By Nick Paul Taylor Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. With the pair preparing to go head to head in a rare disease market, the companies signed up to be the top two sponsors of the newly launched National Triglyceride Alliance. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now.
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
